Abstract This study was carried out to investigate the anti-carcinogenic effect of L-carnosine in human carcinoma cells (SNU-423). The SNU-423 cancer cells were cultured at a density of 2 9 10 4 cells/well in Dulbecco modified Eagle medium. After 24 h of adherence, the cells were treated with L-carnosine (0.2 and 1 mg/mL) for 48 h. Then, cell viability was assessed by sulforhodamine assay, while mitochondrial dysfunction was measured by fluorescence microscopy using chromatin-specific dye Hoechst 33258. Intracellular levels of ROS were assayed by fluorescence spectroscopy with 2 0 ,7 0 -dichlorofluorescein diacetate (DCFDA). L-Carnosine significantly inhibited the growth of the SNU-423 cells (p \ 0.05).
Introduction
Apoptosis is a highly regulated process of programmed cell death (Muthuraman et al. 2016a) . During the apoptotic process, cancer cells undergo a well-regulated program which plays a significant role in the cancer prevention and treatment (Reed 2007) . Darzynkiewicz et al. (1997) have reported that cell shrinkage and nuclear condensation are characteristic features of apoptosis. Un-regulated cell growth is a key event in tumor development (Muthuraman et al. 2014 (Muthuraman et al. , 2016b .
Natural compounds have been recognized as important factors in disease prevention and treatment. Lcarnosine, a dipeptide composed of beta-alanine and histidine, is present at high levels in animal brain and skeletal muscle (Muthuraman et al. 2016c) . The primary sources of L-carnosine are chicken, lean beef, and fish. It is recommended that humans take in 300-600 mg of L-carnosine daily. Studies have shown that L-carnitine possesses antioxidant, anti-glycating, anti-inflammatory, and metal-chelating properties. The anti-proliferative effect of L-carnitine has been reported in mammalian cells (Iovine et al. 2012) , and in NIH3T3-HER2/neu mouse model (Renner et al. 2012 ).
The present study was aimed at investigating the anticancer effect of carnosine in human liver cancer cells.
Materials and methods

Materials
Dulbecco modified Eagle medium (DMEM), fetal bovine serum (FBS), penicillin-streptomycin, and trypsin-EDTA were obtained from Sigma-Aldrich (St. Louis, MO, USA). L-carnosine, dimethyl sulphoxide (DMSO), sulforhodamine B (SRB), Mito Tracker Red and Hoechst 33258 were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Rabbit polyclonal anticaspase-3 antibodies were purchased from Santa Cruz Biotechnology. Donkey Anti-Rabbit IgG H&L (FITC) conjugated secondary antibody was purchased from Abcam (Cambridge Science Park, Cambridge, UK).
Cell culture
Liver carcinoma cells (SNU-423) were purchased from ATCC (CRL-2238 TM ) and were cultured in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin. The SNU-423 cells were maintained in a 5% CO 2 incubator at 37°C. Sulforhodamine B (SRB) assay SNU-423 cells were cultured (2 9 10 4 cells/well) and grown in 96-well plates and allowed to adhere for 24 h at 37°C. The cells were then incubated with Lcarnosine at different concentrations (0.2-1 mg/mL) for 48 h. At the end of 48 h, they were fixed with acetone and air-dried. Thereafter, 100% SRB solution was added to each well, and the wells were incubated for 3 h at room temperature. The micro plates were then washed with 1% acetic acid dried in a drying oven and photographed using an inverted light microscope. Finally, 10 mM Tris base was added, and the plates were left overnight for complete dissolution of SRB. The absorbance of the solution was measured at 540 nm (Muthuraman et al. 2015) .
Assay of mitochondrial dysfunction
Nuclear changes indicative of apoptosis were determined using chromatin-specific dye Hoechst 33258. The SNU-423 cancer cells were cultured at a density of 2 9 10 4 cells/well in DMEM supplemented with FBS and penicillin-streptomycin. After 24 h of adherence, the cells were treated with L-carnosine (0.6, 0.8, and 1 mg/mL) for 48 h. At the end of treatment period, cells were washed twice with PBS and exposed to 40 nM Mito Tracker Red for 30 min at room temperature and washed twice with PBS. Then, cells were exposed to 0.5 lg/mL of Hoechst 33258 for 15 min at room temperature (Bonner et al. 2010) . Thereafter, the cells were washed thrice with PBS and examined under a fluorescent microscope (Axiovert 2000, Carl Zeiss, Germany).
Determination of intracellular ROS levels SNU-423 cancer cells were cultured at a density of 2 9 10 4 cells/well in DMEM supplemented with FBS and penicillin-streptomycin. After 24 h of adherence, the cells were treated with L-carnosine (0.6, 0.8, and 1 mg/mL) for 48 h. Thereafter, the growth medium was removed, and the cells were washed thrice with PBS and incubated with 10 lM of 2 0 ,7 0 -dichlorofluorescein diacetate (DCFDA) for 30 min. Then, fluorescence was determined in a fluorescent plate reader (Axiovert 2000, Carl Zeiss, Oberkochen, Germany) (Muthuraman et al. 2015) , and the fluorescence intensity was expressed as relative fluorescence unit (RFU).
Statistical analysis
Data are expressed as mean ± SEM. Statistical analysis was performed using one-way analysis of variance ANOVA (SPSS 17, Chicago, IL, USA) and Student ''t'' test was carried out. p \ 0.05 was considered statistically significant.
Results and discussion
L-Carnosine significantly inhibited the growth of SNU-423 cancer cells when compared to the control (p \ 0.05), with up to 25% growth inhibition at the highest concentration used (Figs. 1, 2) . Normal mitochondrial morphology was found in the untreated control cells. However, L-carnosine treatment (0.8 and 1 mg/mL) significantly altered the mitochondrial morphology of the SNU-423 cancer cells. In the Lcarnosine treated liver cancer cells, mitochondria appeared as a condensed and clumpy (Fig. 3) .
Intracellular ROS levels were significantly increased in a dose-dependent manner. The fluorescence intensity was measured and expressed as relative fluorescence unit (p \ 0.05). The RFU was increased in a dose-dependent manner by L-carnosine, with values of 79.43, 186.87 and 400.89 for 0.6, 0.8 and 1 mg/mL of L-carnosine, respectively (p \ 0.05, Fig. 4 ).
Our present study investigated anticancer effect of natural dipeptide substance L-carnosine against human liver cancer cells. Our experimental result indicates that L-carnosine could be potential therapeutic agent to inhibit the liver cancer cells. In this study, L-carnosine inhibited cancer cell growth even at the lowest physiological concentration. Renner et al. (2008) have reported that Lcarnosine incubation significantly inhibited the growth of primary glioblastoma cells. The potential of L-carnosine as a treatment strategy for autistic spectrum disorder has been reported (Chez et al. 2012) . Several studies have shown that L-carnosine is a dipeptide model for studying the uptake of materials in the brain cells (Schulz et al. 1987) . The removal of cellular ROS is necessary for the maintenance of cellular homeostatic. Increased cellular levels of ROS inhibit cancer cell growth. LCarnosine has been reported to have several functional roles in the cellular system such as metal chelation, neurotransmitter, pH-buffering and anticell death properties (Dickinson and Chang 2012; Ramsey and Sharpless 2006) . Kohen et al. (1988) have reported the ROS scavenging potential of Lcarnosine, which is believed to be an essential property of an anticancer agent. Moreover, Lcarnosine has been reported to reduce lipid peroxidation and senescence (Gallant et al. 2000; Fontana et al. 2002; Hipkiss et al. 1998) . 
Conclusion
The results obtained in this study demonstrate that Lcarnosine significantly inhibited the growth of SNU-423 liver cancer cells in a dose-dependent manner. Thus, L-carnosine has promising potential as a dipeptide for the effective arrest of the proliferation of human liver cancer cells.
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